IOVA
Iovance Biotherapeutics, Inc. NASDAQ Listed Oct 15, 2010$3.91
-0.51%
vs $3.93
Mkt Cap $1.4B
52w Low $1.69
59.7% of range
52w High $5.41
50d MA $3.78
200d MA $2.97
P/E (TTM)
—
EV/EBITDA
—
P/B
2.0x
Debt/Equity
0.1x
ROE
-56.0%
P/FCF
-4.2x
RSI (14)
46.20
ATR (14)
$0.34
Beta
0.76
50d MA
$3.78
200d MA
$2.97
Avg Volume
14.5M
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
825 Industrial Road · San Carlos, CA 94070 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 4.09 | -14.2% | -13.2% | +2.0% | +2.2% | -3.8% | +2.8% | — |
| Feb 24, 2026 | AMC | -0.22 | -0.18 | +18.2% | 3.78 | +10.3% | +1.3% | -1.0% | +1.8% | -1.8% | -1.1% | — |
| Nov 6, 2025 | AMC | -0.29 | -0.25 | +13.8% | 2.31 | -2.6% | -0.4% | +3.0% | +11.8% | -4.2% | -5.1% | — |
| Aug 7, 2025 | AMC | -0.29 | -0.33 | -13.8% | 2.64 | -27.7% | -20.1% | -6.6% | +13.2% | +9.9% | +0.0% | — |
| May 8, 2025 | AMC | -0.25 | -0.36 | -44.0% | 3.17 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% | — |
| Feb 27, 2025 | AMC | -0.26 | -0.26 | +0.0% | 5.26 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% | — |
| Nov 7, 2024 | AMC | -0.31 | -0.28 | +9.7% | 12.28 | -13.1% | -13.8% | +0.6% | -9.0% | -7.1% | -4.6% | — |
| Aug 8, 2024 | AMC | -0.37 | -0.34 | +8.1% | 7.94 | +18.3% | +24.9% | +1.7% | +6.4% | -5.9% | +5.5% | — |
| May 9, 2024 | AMC | -0.45 | -0.42 | +6.7% | 13.45 | -3.0% | -18.4% | -0.8% | -1.5% | -0.4% | -2.3% | — |
| Feb 28, 2024 | AMC | -0.44 | -0.45 | -2.3% | 17.43 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% | — |
| Nov 7, 2023 | AMC | -0.46 | -0.46 | +0.0% | 4.32 | +3.9% | -3.5% | -5.3% | +0.5% | +1.5% | +16.9% | — |
| Aug 8, 2023 | AMC | -0.81 | -0.47 | +42.0% | 7.14 | -0.7% | +6.4% | -5.4% | -1.8% | +0.8% | +5.5% | — |
| May 9, 2023 | AMC | -0.84 | -0.50 | +40.5% | 7.36 | +3.5% | +3.8% | -1.8% | -0.4% | +5.0% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Chardan Capital | Maintains | Buy → Buy | — | $4.01 | $3.99 | -0.5% | -7.7% | -6.5% | +5.2% | +4.9% | -0.5% |
| Mar 5 | UBS | Maintains | Neutral → Neutral | — | $4.26 | $4.21 | -1.2% | +7.5% | +12.0% | +5.5% | -3.9% | -6.9% |
| Mar 3 | Citizens | Upgrade | Market Perform → Market Outperform | — | $3.79 | $3.62 | -4.5% | -1.1% | +13.6% | +7.5% | +12.0% | +5.5% |
| Feb 25 | Citizens | Upgrade | Market Perform → Market Outperform | — | $3.78 | $4.17 | +10.3% | +1.3% | -1.0% | +1.8% | -1.8% | -1.1% |
| Feb 25 | Barclays | Maintains | Overweight → Overweight | — | $3.78 | $4.17 | +10.3% | +1.3% | -1.0% | +1.8% | -1.8% | -1.1% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $2.25 | $2.26 | +0.4% | +12.0% | -2.4% | +0.8% | +12.1% | +1.4% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $2.24 | $2.28 | +1.8% | +11.6% | -0.8% | -1.6% | +1.2% | -9.7% |
| Nov 6 | Chardan Capital | Maintains | Buy → Buy | — | $1.81 | $2.26 | +24.9% | +27.6% | -0.4% | +3.0% | +11.8% | -4.2% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.19 | $2.16 | -1.4% | -8.7% | -2.5% | +1.0% | -1.0% | -6.7% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.81 | +12.4% | +4.0% | -2.7% | +0.4% | +5.9% | -5.9% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.64 | $1.91 | -27.7% | -20.1% | -6.6% | +13.2% | +9.9% | +0.0% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $2.64 | $1.91 | -27.7% | -20.1% | -6.6% | +13.2% | +9.9% | +0.0% |
| Jul 23 | Chardan Capital | Maintains | Buy → Buy | — | $3.13 | $3.75 | +19.8% | +26.8% | -17.1% | -4.9% | -5.8% | -1.0% |
| May 16 | UBS | Downgrade | Buy → Neutral | — | $1.76 | $1.70 | -3.4% | -5.7% | +10.2% | +4.4% | -7.9% | -0.6% |
| May 12 | Goldman Sachs | Maintains | Buy → Buy | — | $1.75 | $1.85 | +5.7% | +10.3% | -7.3% | -4.5% | +2.9% | -5.7% |
| May 12 | Mizuho | Maintains | Outperform → Outperform | — | $1.75 | $1.85 | +5.7% | +10.3% | -7.3% | -4.5% | +2.9% | -5.7% |
| May 12 | Barclays | Maintains | Overweight → Overweight | — | $1.75 | $1.85 | +5.7% | +10.3% | -7.3% | -4.5% | +2.9% | -5.7% |
| May 9 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $3.17 | $1.94 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $3.17 | $1.94 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $1.94 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $3.07 | $3.05 | -0.7% | -0.3% | +0.7% | +4.2% | -0.6% | +5.3% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $3.30 | $3.37 | +2.1% | +3.3% | -5.3% | -5.0% | -0.3% | +0.7% |
| Mar 3 | Goldman Sachs | Maintains | Buy → Buy | — | $4.24 | $4.27 | +0.7% | -4.7% | -3.0% | +3.3% | -7.4% | +0.0% |
| Mar 3 | Truist | Maintains | Buy → Buy | — | $4.24 | $4.27 | +0.7% | -4.7% | -3.0% | +3.3% | -7.4% | +0.0% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $4.24 | $4.27 | +0.7% | -4.7% | -3.0% | +3.3% | -7.4% | +0.0% |
| Feb 28 | Baird | Maintains | Outperform → Outperform | — | $5.26 | $3.93 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% |
| Feb 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.26 | $3.93 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.26 | $3.93 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% |
| Jan 31 | Piper Sandler | Maintains | Neutral → Neutral | — | $6.21 | $6.12 | -1.4% | -5.8% | -3.6% | +3.0% | +5.0% | -3.6% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.66 | $12.09 | +3.7% | +4.1% | +1.2% | -13.8% | +0.6% | -9.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.92 | $9.97 | +0.5% | +1.7% | +6.4% | -5.9% | +5.5% | -1.6% |
| Jul 29 | Piper Sandler | Downgrade | Overweight → Neutral | — | $9.25 | $8.43 | -8.9% | -2.2% | -1.0% | -2.6% | -6.5% | -4.5% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.01 | $8.05 | +0.5% | +0.1% | +0.5% | -4.1% | -4.4% | -1.5% |
| Jun 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.00 | $7.82 | -2.2% | -0.4% | +0.5% | +1.9% | +3.6% | -4.0% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.88 | $8.87 | -0.1% | -5.7% | -3.2% | +2.7% | -2.2% | -4.4% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.00 | $8.99 | -0.1% | -1.3% | -5.7% | -3.2% | +2.7% | -2.2% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.26 | $10.87 | +5.9% | -2.4% | -3.1% | -4.3% | -3.0% | -1.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $13.04 | -3.0% | -18.4% | -0.8% | -1.5% | -0.4% | -2.3% |
| Mar 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.73 | $14.70 | -0.2% | -3.5% | -2.1% | +0.9% | -0.9% | +7.4% |
| Mar 7 | Truist | Maintains | Buy → Buy | — | $17.16 | $17.40 | +1.4% | -3.1% | -5.5% | -3.8% | -2.5% | +0.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.79 | $18.10 | +7.8% | +1.0% | -2.8% | +4.1% | -3.1% | -5.5% |
| Mar 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.91 | $16.36 | +2.8% | +5.5% | +1.0% | -2.8% | +4.1% | -3.1% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.43 | $16.83 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% |
| Feb 29 | Barclays | Maintains | Overweight → Overweight | — | $17.43 | $16.83 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% |
| Feb 29 | Goldman Sachs | Maintains | Buy → Buy | — | $17.43 | $16.83 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% |
| Feb 21 | Goldman Sachs | Maintains | Buy → Buy | — | $12.03 | $12.10 | +0.6% | +31.1% | +1.1% | -1.1% | +5.3% | +5.2% |
| Feb 20 | Goldman Sachs | Maintains | Buy → Buy | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
| Feb 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
| Feb 20 | Chardan Capital | Maintains | Buy → Buy | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
No insider trades available.
8-K · 8.01
!! High
Iovance Biotherapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 10
8-K · 2.02
!! High
Iovance Biotherapeutics, Inc. -- 8-K 2.02: Earnings Results
Iovance Biotherapeutics reported financial results and operational updates via press release, though the specific performance metrics and guidance changes require reviewing the full disclosure for investor impact assessment.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Inovio's executive departure suggests potential leadership instability that could delay clinical programs or vaccine commercialization efforts, creating near-term uncertainty for investors betting on the company's pipeline success.
Mar 20
8-K · 8.01
!! High
Iovance Biotherapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Iovance Biotherapeutics updated its corporate presentation materials for healthcare conferences and investor meetings, signaling potential strategic updates or progress in its pipeline that management wants to communicate to investors.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 16,617,737 | $58M | New | Mar 2026 |
| 2 | Morgan Stanley | 18,383,680 | $50M | Added | Dec 2025 |
| 3 | Two Sigma Investments, Lp | 13,687,433 | $48M | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 11,700,844 | $41M | New | Mar 2026 |
| 5 | Millennium Management | 9,414,292 | $33M | Added | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 8,490,119 | $30M | Added | Mar 2026 |
| 7 | D.e. Shaw & Co | 8,016,353 | $28M | Added | Mar 2026 |
| 8 | Nuveen, Llc | 3,664,278 | $13M | Added | Mar 2026 |
| 9 | Hrt Financial Lp | 3,486,299 | $12M | Reduced | Mar 2026 |
| 10 | Susquehanna International Group, Llp | 2,996,743 | $11M | Reduced | Mar 2026 |
| 11 | Northern Trust Corp | 2,875,526 | $10M | Added | Mar 2026 |
| 12 | Jane Street Group, Llc | 3,583,810 | $10M | Added | Dec 2025 |
| 13 | Citadel Advisors Llc | 2,611,345 | $9M | Reduced | Mar 2026 |
| 14 | Jpmorgan Chase & Co | 2,500,624 | $8M | Reduced | Mar 2026 |
| 15 | Marshall Wace, Llp | 2,355,612 | $8M | New | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 2,071,524 | $7M | New | Mar 2026 |
| 17 | Rhenman & Partners Asset Management Ab | 2,055,327 | $7M | Added | Mar 2026 |
| 18 | Ubs Group Ag | 1,916,704 | $7M | Added | Mar 2026 |
| 19 | Knott David M Jr | 1,600,000 | $6M | New | Mar 2026 |
| 20 | Invesco Ltd. | 1,422,317 | $5M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.40B
Enterprise Value
$1.10B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.17x
P/B
2.00x
P/S
4.89x
P/FCF
-4.16x
EV/EBITDA
—
Shares Out
357.3M
Financials (TTM)
Revenue
$285.6M
Net Income
-$353.9M
EBITDA
-$321.3M
Free Cash Flow
-$336.2M
Op Cash Flow
-$302.4M
EPS Basic
$-1.09
EPS Diluted
$-0.92
EPS Forward
$-0.53
Gross Margin
114.5%
Op Margin
-127.2%
Net Margin
-123.9%
Balance Sheet
Total Assets
$913.2M
Total Liab.
$214.6M
Total Equity
$698.6M
Cash
$297.0M
LT Debt
$0
Book Value/Sh
$1.95
Debt/Equity
0.07x
Current Ratio
3.20
Quick Ratio
2.83
Returns & Growth
ROE
-56.0%
ROA
-42.8%
ROIC
-51.5%
Rev Growth YoY
+60.6%
EPS Growth YoY
+14.8%
Price Returns
2W
+16.5%
1M
+22.0%
3M
+6.2%
6M
+66.0%
12M
+134.3%
Technicals
52W High
$5.41
52W Low
$1.69
50d MA
$3.78
200d MA
$2.97
RSI (14)
46.20
ATR (14)
$0.34
Beta
0.76
Avg Volume
14.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.00
High
$2.00
Low
$2.00
Median
$2.00
Data updated apr 25, 2026 4:01pm
· Source: financialmodelingprep.com